{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:32:18Z","timestamp":1795195938049,"version":"4.10.3"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.113973","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T16:42:54Z","timestamp":1709311374000},"page":"113973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma \u2013 A phase II randomised trial"],"prefix":"10.1016","volume":"202","author":[{"given":"Vilde Drageset","family":"Haakensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa Kristina","family":"\u00d6jlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solfrid","family":"Thunold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee L.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-2200","authenticated-orcid":false,"given":"Oscar","family":"Grundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika Maria","family":"Szejniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Cedres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Benn","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonje Sofie","family":"Dalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Lund-Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjaan\u00e6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-0275","authenticated-orcid":false,"given":"\u00c5slaug","family":"Helland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.113973_bib1","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ejca.2024.113973_bib2","first-page":"260","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Publ Group"},{"key":"10.1016\/j.ejca.2024.113973_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicenter, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113973_bib4","first-page":"1","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"6736","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.113973_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA8505","article-title":"IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial","volume":"41","author":"Chu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113973_bib6","first-page":"1219","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023"},{"key":"10.1016\/j.ejca.2024.113973_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in pt with locally advanced or metastatic pancreatic cancer","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.113973_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"Jun;21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer Nat Res"},{"key":"10.1016\/j.ejca.2024.113973_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.lungcan.2010.12.023","article-title":"Telomerase activity in pleural malignant mesotheliomas","volume":"73","author":"Au","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2024.113973_bib10","article-title":"Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials","volume":"10","author":"Ellingsen","year":"2022","journal-title":"J Immunother Cancer BMJ"},{"key":"10.1016\/j.ejca.2024.113973_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.572172","article-title":"Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Brunsvig","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113973_bib12","first-page":"232","article-title":"NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma","volume":"19","author":"Haakensen","year":"2021","journal-title":"J Transl Med BioMed Cent Ltd"},{"key":"10.1016\/j.ejca.2024.113973_bib13","first-page":"257","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol [Internet] Elsevier Mass SAS"},{"key":"10.1016\/j.ejca.2024.113973_bib14","article-title":"Variability of tumor area measurements for response assessment in malignant pleural mesothelioma","volume":"40","author":"Labby","year":"2013","journal-title":"MedPhys"},{"key":"10.1016\/j.ejca.2024.113973_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1634\/theoncologist.2016-0121","article-title":"Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma","volume":"22","author":"Wang","year":"2017","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:09:12Z","timestamp":1727410152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":15,"alternative-id":["S0959804924001291"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113973","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma \u2013 A phase II randomised trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113973"}}